Monoclonal antibody effective in treating life-threatening renal disease

June 6, 2013, Emory University

(Medical Xpress)—Two clinical studies have shown that the monoclonal antibody eculizumab is effective in treating patients with atypical hemolytic uremic syndrome (aHUS), a life-threatening, chronic, and progressive inflammatory disease.

The results are published this week in the New England Journal of Medicine.

One of the four sites for the clinical trial in the United States was at Emory University School of Medicine and Children's Healthcare of Atlanta, and was led by principal investigator Larry Greenbaum, MD, PhD, Marcus Professor of Pediatrics at Emory and chief of nephrology at Children's. The trial was conducted in the Pediatric Research Center affiliated with the Atlanta Clinical and Translational Science Institute (ACTSI), part of the CTSA network sponsored by the National Institutes of Health.

aHUS leads to thrombotic microangiopathy (TMA), which causes blood clots in capillaries and small blood vessels. Patients with aHUS have a lifelong risk of systemic complications of TMA, including damage to multiple organ systems.

Although aHUS was previously managed with plasma exchange or infusion (PE/PI), the underlying problems persist, and end-stage or death occurs in approximately 33 to 40 percent of patients during the first clinical episode. Within a year, up to 65 percent of patients managed with PE/PI have permanent , progress to end-stage renal disease, or die. In aHUS patients who have kidney transplants, 60 to 90 percent lose the transplants within a year.

Eculizumab binds to the human C5 complement protein and blocks production of pro-. It was previously approved for the treatment of the blood disorder paroxysmal nocturnal hemoglobinuria (PNH), and the results of these trials led to of eculizumab for the treatment of aHUS.

The two Phase 2 studies enrolled a total of 37 patients who were not responding to PE/PI or who had no platelet count decrease >25 percent for 8 weeks during PE/PI. Participants in each study were treated for 26 weeks and longer-term extensions. Effectiveness was measured by an increase in platelet counts and TMA event-free status (no platelet decrease >25 percent, PE/PI, or new dialysis). Secondary measures were renal outcomes, health-related quality of life, and safety.

The studies found that eculizumab significantly reduced complement-mediated TMA, as indicated by normalization of hematologic measures and reduction in interventions for TMA. In the first trial, the platelet count significantly increased from baseline. In the second, 80 percent of the patients had TMA event–free status.

Eculizumab also resulted in significant improvement in all secondary measurements. In one of the studies, four out of five patients receiving dialysis were able to discontinue dialysis following initiation of eculizumab. Earlier intervention was associated with significantly greater improvement in kidney function. No cumulative toxicity or serious infection-related adverse events were found.

"This study showed that eculizumab is effective in treating patients with this chronic, life-threatening disease, and we were pleased to be one of the participating sites," says Greenbaum. "This drug is a true therapeutic breakthrough for these ."

Explore further: Certain mutations affect kidney disease risk and prognosis

Related Stories

Certain mutations affect kidney disease risk and prognosis

February 21, 2013
Certain gene mutations affect individuals' risk of developing a serious kidney condition, as well as their prognosis after being diagnosed with the disease, according to a study appearing in an upcoming issue of the Journal ...

Antibodies successful in the treatment of the hemolytic-uremic syndrome from EHEC

May 31, 2011
In the online version of the New England Journal of Medicine, physicians and scientists in Heidelberg, Montreal, and Paris reported on the successful treatment of three young children who were suffering from a severe hemolytic-uremic ...

Quality of life and treatment of late-stage chronic kidney disease

September 11, 2012
Renal transplantation is best treatment option for improving quality of life in people with late-stage chronic kidney disease

Racial disparities exist in end-of-life care for US dialysis patients

April 11, 2013
At the end of life, black patients with kidney failure receiving chronic dialysis are less likely to be referred to hospice and to discontinue dialysis compared with white patients, according to a study appearing in an upcoming ...

Robotic transplant an option for obese kidney patients

May 15, 2013
Obese patients who received robotic kidney transplants had fewer wound complications than patients who received traditional "open" transplant surgery, according to surgeons at the University of Illinois Hospital & Health ...

Routine cinacalcet for end stage kidney disease not warranted

April 30, 2013
Cinacalcet, a drug commonly given to patients with end stage kidney disease to help keep phosphorus and parathyroid blood levels within a target range and has few patient level clinical benefits and several adverse effects, ...

Recommended for you

Marker may help target treatments for Crohn's patients

October 16, 2018
Crohn's disease (CD), a chronic inflammatory condition of the intestinal tract, has emerged as a global disease, with rates steadily increasing over the last 50 years. Experts have long suspected that CD likely represents ...

Polio: Environmental monitoring will be key as world reaches global eradication

October 15, 2018
Robust environmental monitoring should be used as the world approaches global eradication of polio, say University of Michigan researchers who recently studied the epidemiology of the 2013 silent polio outbreak in Rahat, ...

Study traces hospital-acquired bloodstream infections to patients' own bodies

October 15, 2018
The most common source of a bloodstream infection acquired during a hospital stay is not a nurse's or doctor's dirty hands, or another patient's sneeze or visitor's cough, but the patient's own gut, Stanford University School ...

Researchers make essential imaging tests safer for people at risk of acute kidney injury

October 15, 2018
Every year, millions of people undergo medical tests and procedures, such as coronary angiography, which use intravascular contrast dyes. "For the majority of patients, these are safe and necessary procedures. However, about ...

Medical marijuana might help MS patients, but uncertainty remains

October 13, 2018
Medical products derived from marijuana might have a mild benefit in treating symptoms of multiple sclerosis, based on reports from patients.

Do not give decongestants to young children for common cold symptoms, say experts

October 11, 2018
Decongestants should not be given to children under 6—and given with caution in children under 12—as there is no evidence that they alleviate symptoms such as a blocked or runny nose, and their safety is unclear, say ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.